Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques

Journal of Virology

Volumn 74, Issue 4, 2000, Pages 1704-1711

  Rosenwirth, Brigitte ^a   Ten Haaft, Peter ^a   Bogers, Willy M J M ^a   Nieuwenhuis, Ivonne G ^a   Niphuis, Henk ^a   Kuhn, Eva Maria ^a   Bischofberger, Norbert ^b   Heeney, Jonathan L ^a   Überla, Klaus ^c  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANIMALS; ANTI-HIV AGENTS; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP120; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LYMPHOCYTE SUBSETS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 0033944616     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.4.1704-1711.2000     Document Type: Article

References (32)

1. Almond, N. M., and J. L. Heeney. 1998. AIDS vaccine development in primate models. AIDS 12(Suppl. A):S133-S140.
2. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
3. Balzarini, J., S. Aquaro, C. F. Perno, M. Witvrouw, A. Holy, and E. De Clercq. 1996. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219:337-341.
4. Balzarini, J., A. Holy, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37: 332-338.
5. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
6. Cardo, D. M., D. H. Culver, C. A. Ciesielski, P. U. Srivastava, R. Marcus, D. Abiteboul, J. Heptonstall, G. Ippolito, F. Lot, P. S. McKibben, and D. M. Bell. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N. Engl. J. Med. 337:1485-1490.
7. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78-86.
8. Daar, E. S., J. Bai, M. A. Hausner, M. Majchrowicz, M. Tamaddon, and J. V. Giorgi. 1998. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann. Intern. Med. 128: 827-829.
9. Desrosiers, R. C. 1996. Live attenuated vaccines: best hope to prevent HIV? HIV Adv. Res. Ther. 3:3-9.
10. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
11. Douek, D. C., R. D. McFarland, P. H. Keiser, E. A. Gage, J. M. Massey, B. F. Haynes, M. A. Polis, A. T. Haase, M. B. Feinberg, J. L. Sullivan, B. D. Jamieson, J. A. Zack, L. J. Picker, and H. A. Koup. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
12. Heeney, J. L., L. Holterman, P. ten Haaft, R. Dubbes, W. Koornstra, V. Teeuwsen, P. Bourquin, S. Norley, and H. Niphuis. 1994. Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res. Hum. Retroviruses 10(Suppl. 2):S117-S121.
13. Hoch, J., S. M. Lang, M. Weeger, C. Stahl-Hennig, C. Coulibaly, U. Dittmer, G. Hunsmann, D. Fuchs, J. Müller, S. Sopper, B. Fleckenstein, and K. T. Überla. 1995. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813.
14. Johnson, R. P. 1999. Live attenuated AIDS vaccines: hazards and hopes. Nat. Med. 5:154-155.
15. Kestler, H. W., D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
16. Lackner, A. A. 1994. Pathology of simian immunodeficiency virus induced disease. Curr. Top. Microbiol. Immunol. 188:35-64.
17. Lewis, M. G., S. Bellah, K. McKinnon, J. Yalley-Ogunro, P. M. Zack, W. R. Elkins, R. C. Desrosiers, and G. A. Eddy. 1994. Titration and characterization of two rhesus derived SIVmac challenge stocks. AIDS Res. Hum. Retroviruses 10:213-220.
18. Li, T. S., R. Tubiana, C. Kallama, V. Calvez, M. H. Ait, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 1682-1686.
19. Lisziewicz, J., E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori. 1999. HIV control following discontinuation of antiretroviral therapy. N. Engl. J. Med. 340:1683-1684.
20. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
21. Pantaleo, G., S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, and L. K. Schrager. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209-216.
22. Perrin, L., A. Rakik, S. Yerly, C. Baumberger, L. S. Kinloch-de, M. Pechere, and B. Hirschel. 1996. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS 10:1233-1237.
23. Shibata, R., C. Siemon, S. C. Czajak, R. C. Desrosiers, and M. A. Martin. 1997. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71:8141-8148.
24. ten Haaft, P., B. Verstrepen, K. Überla, B. Rosenwirth, and J. Heeney. 1998. A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques. J. Virol. 72:10281-10285.
25. mnc infection depends critically on timing of initiation and duration of treatment. J. Virol. 72:4265-4273.
26. Tsai, C. C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischolberger, and P. J. Dailey. 1997. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine mono-therapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-712.
27. Tsai, C. C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
28. Überla, K., C. Stahl Hennig, D. Böttiger, K. Mätz-Rensing, F. J. Kaup, J. Li, W. A. Haseltine, B. Fleckenstein, G. Hunsmann, B. Öberg, and J. Sodroski. 1995. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 92:8210-8214.
29. Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas. 1999. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J. Virol. 73:2947-2955.
30. Watson, A., J. McClure, J. Ranchalis, M. Scheibel, A. Schmidt, B. Kennedy, W. R. Morton, N. L. Haigwood, and S. L. Hu. 1997. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res. Hum. Retroviruses 13:1375-1381.
31. Watson, A., J. Ranchalis, B. Travis, J. McClure, W. Sutton, P. R. Johnson, S. L. Hu, and N. L. Haigwood. 1997. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71:284-290.
32. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.